{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:15:38Z","timestamp":1762431338150,"version":"3.37.3"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,9,25]],"date-time":"2017-09-25T00:00:00Z","timestamp":1506297600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,9,25]],"date-time":"2017-09-25T00:00:00Z","timestamp":1506297600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["KL2 TR000081"],"award-info":[{"award-number":["KL2 TR000081"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s10549-017-4507-y","type":"journal-article","created":{"date-parts":[[2017,9,25]],"date-time":"2017-09-25T13:24:15Z","timestamp":1506345855000},"page":"277-288","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Obesity and survival in the neoadjuvant breast cancer setting: role of tumor subtype in an ethnically diverse population"],"prefix":"10.1007","volume":"167","author":[{"given":"Ying L.","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anurag","family":"Saraf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Catanese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shing M.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eileen P.","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Kalinsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,9,25]]},"reference":[{"issue":"9945","key":"4507_CR1","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/S0140-6736(14)60892-8","volume":"384","author":"K Bhaskaran","year":"2014","unstructured":"Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, Smeeth L (2014) Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. Lancet 384(9945):755\u2013765","journal-title":"Lancet"},{"issue":"1","key":"4507_CR2","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.1467-789X.2009.00708.x","volume":"12","author":"AG Tsai","year":"2011","unstructured":"Tsai AG, Williamson DF, Glick HA (2011) Direct medical cost of overweight and obesity in the USA: a quantitative systematic review. Obesity Rev 12(1):50\u201361","journal-title":"Obesity Rev"},{"issue":"6","key":"4507_CR3","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1007\/s12282-015-0638-3","volume":"22","author":"WG Gathirua-Mwangi","year":"2015","unstructured":"Gathirua-Mwangi WG, Zollinger TW, Murage MJ, Pradhan KR, Champion VL (2015) Adult BMI change and risk of breast cancer: National Health and Nutrition Examination Survey (NHANES) 2005\u20132010. Breast Cancer 22(6):648\u2013656","journal-title":"Breast Cancer"},{"issue":"35","key":"4507_CR4","doi-asserted-by":"publisher","first-page":"4203","DOI":"10.1200\/JCO.2016.68.4480","volume":"34","author":"S Jiralerspong","year":"2016","unstructured":"Jiralerspong S, Goodwin PJ (2016) Obesity and breast cancer prognosis: evidence, challenges, and opportunities. J Clin Oncol 34(35):4203\u20134216","journal-title":"J Clin Oncol"},{"issue":"10","key":"4507_CR5","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1093\/annonc\/mdu042","volume":"25","author":"DS Chan","year":"2014","unstructured":"Chan DS, Vieira AR, Aune D et al (2014) Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol 25(10):1901\u20131914","journal-title":"Ann Oncol"},{"issue":"2","key":"4507_CR6","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s10549-012-2073-x","volume":"134","author":"S Niraula","year":"2012","unstructured":"Niraula S, Ocana A, Ennis M, Goodwin PJ (2012) Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis. Breast Cancer Res Treat 134(2):769\u2013781","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"4507_CR7","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s10549-010-0990-0","volume":"123","author":"M Protani","year":"2010","unstructured":"Protani M, Coory M, Martin JH (2010) Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat 123(3):627\u2013635","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"4507_CR8","doi-asserted-by":"publisher","first-page":"R365","DOI":"10.1530\/ERC-15-0400","volume":"22","author":"EH Allott","year":"2015","unstructured":"Allott EH, Hursting SD (2015) Obesity and cancer: mechanistic insights from transdisciplinary studies. Endocr Relat Cancer 22(6):R365\u2013R386","journal-title":"Endocr Relat Cancer"},{"issue":"19","key":"4507_CR9","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1200\/JCO.2010.33.2585","volume":"29","author":"G Pfeiler","year":"2011","unstructured":"Pfeiler G, Konigsberg R, Fesl C et al (2011) Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol 29(19):2653\u20132659","journal-title":"J Clin Oncol"},{"issue":"21","key":"4507_CR10","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.1200\/JCO.2009.27.2021","volume":"28","author":"I Sestak","year":"2010","unstructured":"Sestak I, Distler W, Forbes JF, Dowsett M, Howell A, Cuzick J (2010) Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol 28(21):3411\u20133415","journal-title":"J Clin Oncol"},{"issue":"19","key":"4507_CR11","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1093\/jnci\/djg060","volume":"95","author":"JJ Dignam","year":"2003","unstructured":"Dignam JJ, Wieand K, Johnson KA, Fisher B, Xu L, Mamounas EP (2003) Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer. J Natl Cancer Inst 95(19):1467\u20131476","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"4507_CR12","doi-asserted-by":"publisher","first-page":"5937","DOI":"10.1002\/cncr.27527","volume":"118","author":"JA Sparano","year":"2012","unstructured":"Sparano JA, Wang M, Zhao F et al (2012) Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer 118(23):5937\u20135946","journal-title":"Cancer"},{"issue":"13","key":"4507_CR13","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1002\/cncr.28051","volume":"119","author":"JA Crozier","year":"2013","unstructured":"Crozier JA, Moreno-Aspitia A, Ballman KV, Dueck AC, Pockaj BA, Perez EA (2013) Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831. Cancer 119(13):2447\u20132454","journal-title":"Cancer"},{"issue":"6","key":"4507_CR14","doi-asserted-by":"publisher","first-page":"e0129741","DOI":"10.1371\/journal.pone.0129741","volume":"10","author":"S Hao","year":"2015","unstructured":"Hao S, Liu Y, Yu KD, Chen S, Yang WT, Shao ZM (2015) Overweight as a prognostic factor for triple-negative breast cancers in chinese women. PLoS ONE 10(6):e0129741","journal-title":"PLoS ONE"},{"issue":"17","key":"4507_CR15","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.1016\/j.ejca.2013.07.016","volume":"49","author":"L Mazzarella","year":"2013","unstructured":"Mazzarella L, Disalvatore D, Bagnardi V et al (2013) Obesity increases the incidence of distant metastases in oestrogen receptor-negative human epidermal growth factor receptor 2-positive breast cancer patients. Eur J Cancer 49(17):3588\u20133597","journal-title":"Eur J Cancer"},{"key":"4507_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13058-015-0639-3","volume":"17","author":"P Widschwendter","year":"2015","unstructured":"Widschwendter P, Friedl TW, Schwentner L et al (2015) The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial. Breast Cancer Res 17:129","journal-title":"Breast Cancer Res"},{"issue":"5","key":"4507_CR17","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1001\/jama.2012.39","volume":"307","author":"KM Flegal","year":"2012","unstructured":"Flegal KM, Carroll MD, Kit BK, Ogden CL (2012) Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999\u20132010. JAMA 307(5):491\u2013497","journal-title":"JAMA"},{"issue":"6","key":"4507_CR18","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3945\/an.115.009647","volume":"6","author":"EV Bandera","year":"2015","unstructured":"Bandera EV, Maskarinec G, Romieu I, John EM (2015) Racial and ethnic disparities in the impact of obesity on breast cancer risk and survival: a global perspective. Adv. Nutr. 6(6):803\u2013819","journal-title":"Adv. Nutr."},{"key":"4507_CR19","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.canep.2016.07.018","volume":"45","author":"BR Hunt","year":"2016","unstructured":"Hunt BR, Hurlbert MS (2016) Black:white disparities in breast cancer mortality in the 50 largest cities in the United States, 2005\u20132014. Cancer epidemiology. 45:169\u2013173","journal-title":"Cancer epidemiology."},{"issue":"3","key":"4507_CR20","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s10549-015-3350-2","volume":"150","author":"JR Tichy","year":"2015","unstructured":"Tichy JR, Deal AM, Anders CK, Reeder-Hayes K, Carey LA (2015) Race, response to chemotherapy, and outcome within clinical breast cancer subtypes. Breast Cancer Res Treat 150(3):667\u2013674","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"4507_CR21","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10549-016-3918-5","volume":"159","author":"ET Warner","year":"2016","unstructured":"Warner ET, Ballman KV, Strand C et al (2016) Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426). Breast Cancer Res Treat 159(1):109\u2013118","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"4507_CR22","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1093\/oxfordjournals.aje.a010275","volume":"151","author":"IJ Hall","year":"2000","unstructured":"Hall IJ, Newman B, Millikan RC, Moorman PG (2000) Body size and breast cancer risk in black women and white women: the Carolina Breast Cancer Study. Am J Epidemiol 151(8):754\u2013764","journal-title":"Am J Epidemiol"},{"key":"4507_CR23","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.breast.2016.05.013","volume":"32","author":"F Karatas","year":"2016","unstructured":"Karatas F, Erdem GU, Sahin S et al (2016) Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients. Breast 32:237\u2013244","journal-title":"Breast"},{"issue":"1","key":"4507_CR24","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s10549-015-3287-5","volume":"150","author":"C Fontanella","year":"2015","unstructured":"Fontanella C, Lederer B, Gade S et al (2015) Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials. Breast Cancer Res Treat 150(1):127\u2013139","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"4507_CR25","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1016\/j.clbc.2016.02.018","volume":"16","author":"T Erbes","year":"2016","unstructured":"Erbes T, Stickeler E, Rucker G et al (2016) BMI and pathologic complete response to neoadjuvant chemotherapy in breast cancer: a study and meta-analysis. Clin Breast Cancer 16(4):e119\u2013e132","journal-title":"Clin Breast Cancer"},{"key":"4507_CR26","volume-title":"Physical status: the use and interpretation of anthropometry","author":"WHO","year":"1995","unstructured":"WHO (1995) Physical status: the use and interpretation of anthropometry. WHO, Geneva"},{"issue":"5","key":"4507_CR27","first-page":"303","volume":"5","author":"D Du Bois","year":"1989","unstructured":"Du Bois D, Du Bois EF (1989) A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition 5(5):303\u2013311 discussion 312\u2013303","journal-title":"Nutrition"},{"issue":"4","key":"4507_CR28","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1200\/JOP.777003","volume":"6","author":"ME Hammond","year":"2010","unstructured":"Hammond ME, Hayes DF, Wolff AC, Mangu PB, Temin S (2010) American society of clinical oncology\/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract\/Am Soc Clin Oncol 6(4):195\u2013197","journal-title":"J Oncol Pract\/Am Soc Clin Oncol"},{"key":"4507_CR29","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s00428-015-1871-z","volume":"468","author":"N Tchrakian","year":"2015","unstructured":"Tchrakian N, Flanagan L, Harford J, Gannon JM, Quinn CM (2015) New ASCO\/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers. Virchows Archiv 468:207\u2013211","journal-title":"Virchows Archiv"},{"key":"4507_CR30","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1186\/s40064-015-1116-2","volume":"4","author":"C Zhang","year":"2015","unstructured":"Zhang C, Wang S, Israel HP et al (2015) Higher locoregional recurrence rate for triple-negative breast cancer following neoadjuvant chemotherapy, surgery and radiotherapy. SpringerPlus 4:386","journal-title":"SpringerPlus"},{"issue":"15","key":"4507_CR31","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1200\/JCO.2006.10.3523","volume":"25","author":"CA Hudis","year":"2007","unstructured":"Hudis CA, Barlow WE, Costantino JP et al (2007) Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 25(15):2127\u20132132","journal-title":"J Clin Oncol"},{"issue":"1","key":"4507_CR32","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/S1470-2045(16)30631-3","volume":"18","author":"SJ Luen","year":"2017","unstructured":"Luen SJ, Salgado R, Fox S et al (2017) Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. Lancet Oncol 18(1):52\u201362","journal-title":"Lancet Oncol"},{"issue":"19","key":"4507_CR33","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma S, Miles D, Gianni L et al (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367(19):1783\u20131791","journal-title":"N Engl J Med"},{"issue":"6","key":"4507_CR34","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3390\/ijms17060989","volume":"17","author":"SB Matthews","year":"2016","unstructured":"Matthews SB, Thompson HJ (2016) The obesity-breast cancer conundrum: an analysis of the issues. Int J Mol Sci 17(6):989","journal-title":"Int J Mol Sci"},{"issue":"8","key":"4507_CR35","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nrc3967","volume":"15","author":"AG Renehan","year":"2015","unstructured":"Renehan AG, Zwahlen M, Egger M (2015) Adiposity and cancer risk: new mechanistic insights from epidemiology. Nat Rev Cancer 15(8):484\u2013498","journal-title":"Nat Rev Cancer"},{"key":"4507_CR36","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3389\/fonc.2013.00209","volume":"3","author":"NA Ford","year":"2013","unstructured":"Ford NA, Lashinger LM, Allott EH, Hursting SD (2013) Mechanistic targets and phytochemical strategies for breaking the obesity-cancer link. Front Oncol 3:209","journal-title":"Front Oncol"},{"issue":"2","key":"4507_CR37","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3945\/jn.113.178533","volume":"144","author":"LM Lashinger","year":"2014","unstructured":"Lashinger LM, Ford NA, Hursting SD (2014) Interacting inflammatory and growth factor signals underlie the obesity-cancer link. J Nutr 144(2):109\u2013113","journal-title":"J Nutr"},{"issue":"3","key":"4507_CR38","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1158\/1055-9965.EPI-14-1017","volume":"24","author":"BY Hair","year":"2015","unstructured":"Hair BY, Troester MA, Edmiston SN et al (2015) Body mass index is associated with gene methylation in estrogen receptor-positive breast tumors. Cancer Epidemiol Biomark Prevent 24(3):580\u2013586","journal-title":"Cancer Epidemiol Biomark Prevent"},{"issue":"5","key":"4507_CR39","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1158\/1940-6207.CAPR-15-0348","volume":"9","author":"EL Rossi","year":"2016","unstructured":"Rossi EL, de Angel RE, Bowers LW et al (2016) Obesity-associated alterations in inflammation, epigenetics, and mammary tumor growth persist in formerly obese mice. Cancer Prevent Res 9(5):339\u2013348","journal-title":"Cancer Prevent Res"},{"issue":"Suppl2","key":"4507_CR40","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1016\/j.breast.2013.07.008","volume":"22","author":"PJ Goodwin","year":"2013","unstructured":"Goodwin PJ (2013) Obesity and endocrine therapy: host factors and breast cancer outcome. Breast 22(Suppl2):S44\u2013S47","journal-title":"Breast"},{"issue":"32","key":"4507_CR41","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.1200\/JCO.2011.40.8666","volume":"30","author":"M Ewertz","year":"2012","unstructured":"Ewertz M, Gray KP, Regan MM et al (2012) Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. J Clin Oncol 30(32):3967\u20133975","journal-title":"J Clin Oncol"},{"issue":"3","key":"4507_CR42","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1158\/1940-6207.CAPR-10-0381","volume":"4","author":"K Subbaramaiah","year":"2011","unstructured":"Subbaramaiah K, Howe LR, Bhardwaj P et al (2011) Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prevent Res 4(3):329\u2013346","journal-title":"Cancer Prevent Res"},{"issue":"4","key":"4507_CR43","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.clbc.2013.12.008","volume":"14","author":"M Hubalek","year":"2014","unstructured":"Hubalek M, Oberguggenberger A, Beer B et al (2014) Does obesity interfere with anastrozole treatment? Positive association between body mass index and anastrozole plasma levels. Clin Breast Cancer 14(4):291\u2013296","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"4507_CR44","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s10549-012-2278-z","volume":"136","author":"C Diorio","year":"2012","unstructured":"Diorio C, Lemieux J, Provencher L, Hogue JC, Vachon E (2012) Aromatase inhibitors in obese breast cancer patients are not associated with increased plasma estradiol levels. Breast Cancer Res Treat 136(2):573\u2013579","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"4507_CR45","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1038\/bjc.2014.2","volume":"110","author":"V Sini","year":"2014","unstructured":"Sini V, Lunardi G, Cirillo M et al (2014) Body mass index and circulating oestrone sulphate in women treated with adjuvant letrozole. Br J Cancer 110(5):1133\u20131138","journal-title":"Br J Cancer"},{"issue":"1","key":"4507_CR46","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.maturitas.2010.04.015","volume":"67","author":"AI Phipps","year":"2010","unstructured":"Phipps AI, Ichikawa L, Bowles EJA et al (2010) Defining menopausal status in epidemiologic studies: a comparison of multiple approaches and their effects on breast cancer rates. Maturitas 67(1):60\u201366","journal-title":"Maturitas"},{"issue":"3","key":"4507_CR47","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s10549-014-3048-x","volume":"146","author":"SM George","year":"2014","unstructured":"George SM, Bernstein L, Smith AW et al (2014) Central adiposity after breast cancer diagnosis is related to mortality in the health, eating, activity, and lifestyle study. Breast Cancer Res Treat 146(3):647\u2013655","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"4507_CR48","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1007\/s10552-015-0673-6","volume":"26","author":"X Sun","year":"2015","unstructured":"Sun X, Nichols HB, Robinson W, Sherman ME, Olshan AF, Troester MA (2015) Post-diagnosis adiposity and survival among breast cancer patients: influence of breast cancer subtype. Cancer Causes Control 26(12):1803\u20131811","journal-title":"Cancer Causes Control"},{"key":"4507_CR49","doi-asserted-by":"publisher","unstructured":"Liu YL, Saraf A, Catanese B et al (2017) Obesity and survival in the neoadjuvant breast cancer setting: role of tumor subtype in an ethnically diverse population. Breast Cancer Res Treat. doi:\n                    10.1007\/s10549-017-4507-y","DOI":"10.1007\/s10549-017-4507-y"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-017-4507-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-017-4507-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-017-4507-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T13:03:02Z","timestamp":1589720582000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-017-4507-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,25]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["4507"],"URL":"https:\/\/doi.org\/10.1007\/s10549-017-4507-y","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"type":"print","value":"0167-6806"},{"type":"electronic","value":"1573-7217"}],"subject":[],"published":{"date-parts":[[2017,9,25]]},"assertion":[{"value":"24 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Author EC has received funding from Merck and has served as a consultant for Eisai. Author KK has served as a consultant for Lilly, Biotheranostics, Amgen, Eisai, and Novartis. All other authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}